TNF-alpha antagonist therapy modify the tuberculin skin test response

Rheumatology International

Volumn 31, Issue 9, 2011, Pages 1147-1151

  Cagatay, Tulin ^a   Kilicaslan, Zeki ^a   Cagatay, Penbe ^b   Mertsoylu, Munevver ^a   Gulbaran, Ziya ^a   Yildiz, Reyhan ^a   Pur, Leyla ^a   Kamali, Sevil ^b   Gul, Ahmet ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Ankylosing spondylitis; Latent tuberculosis infection; Rheumatoid arthritis; Tuberculin skin test (TST); Tumour necrosis factor (TNF) antagonist drugs

Indexed keywords

ISONIAZID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFECT; FALSE NEGATIVE RESULT; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOREACTIVITY; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SKIN INDURATION; TUBERCULIN TEST;

ADULT; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; LATENT TUBERCULOSIS; MALE; PROSPECTIVE STUDIES; RHEUMATIC DISEASES; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054948093     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1424-3     Document Type: Article

References (22)

1. World Health Organization (2007) WHO report 2007: global tuberculosis control: surveillance, planning, financing. WHO, Geneva
2. Sester U, Junker H, Junker H et al (2006) Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transplant 21:3258-3268 (Pubitemid 44567103)
3. Saliu OY, Sofer C, Stein DS et al (2006) Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194:486-492 (Pubitemid 44162660)
4. Dukes HC (2004) Infectious complications of treatment with biologic agents: infectious arthritis and immune dysfunction. Curr Opin Rheumatol 16:393-398
5. Vukmanovic-Stejic M, Reed JR, Lacy KE et al (2006) Mantoux test as a model for a secondary immune response in humans. Immunol Lett 107:93-101 (Pubitemid 44779813)
6. Helliwell MG, Panayi GS, Unger A (1984) Delayed cutaneous hypersensitivity in rheumatoid arthritis: the influence of nutrition and drug therapy. Clin Rheumatol 3:39-45
7. Furst DE, Breedveld FC, Kalden JR et al (2003) Updated consensus statement on biological agents for treatment of rheumatoid arthritis and other immune mediated inflammatory diseases. Ann Rheum Dis 62(Suppl 2):2-9 (Pubitemid 37323590)
8. Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Myco-bacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 60:800-805
9. Hamdi H, Mariette X, Godot V et al (2006) The RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8:R114
10. Joven BE, Almodóvar R, Galindo M et al (2006) Does anti-tumour necrosis factor a treatment modify the tuberculin TST response? Ann Rheum Dis 65:699
11. Hill PC, Jeffries DJ, Brookes RH et al (2007) Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts. PLoSONE 2:183
12. Kunst H (2006) Diagnosis of latent tuberculosis infection: the potential role of new technologies. Respir Med 100:2098-2106 (Pubitemid 44724568)
13. Codecasa LR, Ferrarese M, Penati V et al (2005) Comparison of tuberculin skin test and Quantiferon immunological assay for latent tuberculosis infection. Monaldi Arch Chest Dis 63:158-162 (Pubitemid 41700743)
14. Smith MD, Smith A, O'Donnell J et al (1989) Impaired delayed type cutaneous hypersensitivity in rheumatoid arthritis reversed by chrysotherapy. Ann Rheum Dis 48:108-113 (Pubitemid 19062227)
15. Kerksiek KM, Pamer EG (1999) T cell responses to bacterial infections. Curr Opin Immunol 11:400-405
16. Ogawa T, Uchida H, Kusumoto Y et al (1991) Increase in tumor necrosis factor a and interleukin-6 secreting cells in peripheral blood mononuclear cells from subjects infected with Mycobac-terium tuberculosis. Infect Immun 59:30021-30025
17. Bermudez LE, Kaplan G (1995) Recombinant cytokines for controlling mycobacterial infections. Trends Microbiol 3:22-27
18. Kindler V, Sappino AP, Grau GE et al (1989) The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731-740 (Pubitemid 19082507)
19. Flesch IEA, Kaufmann SHE (1990) Activation of tuberculostatic macrophage functions by interferon gamma, interleukin 4 and tumor necrosis factor. Infect Immun 58:269-271
20. Hussain R, Shiratsuchi H, Phillips M et al (2001) Opsonizing antibodies (IgG1) up-regulate monocyte proinflammatory cyto-kines tumour necrosis factor-a (TNF-α) and IL-6 but not anti-inflammatory cytokine IL-10 in mycobacterial antigen-stimulated monocytes-implications for pathogenesis. Clin Exp Immunol 123:210-218 (Pubitemid 32174771)
21. Pachot H, Arnaud B, Marrote H et al (2007) Increased tumor necrosis factor-a mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response. J Rheumatol 34:2158-2161 (Pubitemid 350076873)
22. Marotte H, Maslinski W, Miossec P (2005) Circulating tumour necrosis factor-a bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther 7:149-155